Employment and Executive Compensation

Capital Markets

Corporate / M&A

IP / IT

Vectivio

On April 9, 2021, VectivBio Holding AG announced its initial public offering and listing of its shares on Nasdaq (ticker symbol VECT). VectivBio is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Through its IPO, at USD 17 per share, VectivBio raises gross proceeds of USD 146.6 m (including greenshoe). At market close on the first day of trading, VectivBio had a market capitalization of USD 824 m.
Homburger advises VectivBio Holding AG in this matter. The Homburger team includes partner Andreas Müller (Capital Markets; Corporate / M&amp;A; Employment and Executive Compensation), lead associate Margrit Marti, associates Angela Oppliger and Kevin Hubacher and junior associate Daniel Bötticher (all Capital Markets; Corporate / M&amp;A), partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax), and partner Luca Dal Molin (IP/IT).

Homburger advises VectivBio on its IPO on Nasdaq

Regulatory

Competition

Litigation

Financing and Investment Products

Liberty Global

On November 11, 2020, the all-cash public tender offer by UPC Schweiz GmbH (UPC), a subsidiary of Liberty Global plc, for all publicly held shares of Sunrise Communications Group AG (Sunrise) has been settled. UPC has acquired a 98% stake in Sunrise. The transaction values Sunrise’s equity at CHF 5.0 bn.
Homburger AG is advising Liberty Global on the transaction. The Homburger team is led by partners Daniel Daeniker and Daniel Hasler (Corporate / M&amp;A) and includes partners Richard Stäuber, Franz Hoffet (Competition, Regulatory), Stefan Oesterhelt (Tax), Luca Dal Molin (IP / IT) and Roman Baechler (Litigation), counsel Micha Fankhauser (Corporate / M&amp;A), associates Daniel Häusermann, Karin Mattle, Mirko Stiefel and Stefan Luginbühl (all Corporate / M&amp;A), Yves Bianchi, Ramin Gohari and Jonas J. Krull (Competition, Regulatory), David Borer and Pierina Janett-Seiler (Financing and Investment Products), Marc Vogelsang and Raphaël Fellay (both Tax), Kirsten Wesiak-Schmidt (IP / IT), as well as junior associates Cédric Berger, Géraldine Danuser, Daniel Madani (all Corporate / M&amp;A) and Urs Stürmer (Competition, Regulatory).

Homburger advises Liberty Global on successful settlement of public tender offer for Sunrise

On October 15, 2020, VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has closed a USD 110 m crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfert Initiative and Cowen Healthcare Investments.
Proceeds from the financing will be used to support the further clinical development of VectivBio&#8217;s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives.
The Homburger team was led by partner Andreas Müller and included lead associate Margrit Marti, associates Angela Oppliger and Mirko Stiefel and transaction and corporate support specialist Carolina Rodriguez (all Corporate / M&amp;A), partner Luca Dal Molin and associate Kirsten Schmidt (both IP / IT) as well as partner Stefan Oesterhelt and associates Joël Gyger and Raphaël Fellay (all Tax).

Raphaël
Fellay

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises Liberty Global on successful settlement of public tender offer for Sunrise

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Raphaël Fellay

Career

Languages

Bar Registration

Teams

RaphaëlFellay

Homburger advises VectivBio on its IPO on Nasdaq

Homburger advises Liberty Global on successful settlement of public tender offer for Sunrise

Homburger advises VectivBio on USD 110 m Crossover Financing

Join the Team

Raphaël Fellay

Career

Languages

Bar Registration

Teams

Raphaël
Fellay